secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001493152-25-011597
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon Q2 net loss narrows to $2.7M, cash $4.7M; first patient dosed in Phase 3 ovarian cancer trial
--------------------------------------------------------------------------------

- Net loss $2.7M ($2.15/shr) vs $4.8M ($7.64/shr) YoY; operating expenses down 45% to $2.8M.
- Cash $4.7M at June 30; received $3.1M in July from warrant exercises and ATM; sufficient into Q4 2025.
- First patient dosed July 30 in Phase 3 OVATION 3 trial of IMNN-001 for advanced ovarian cancer; 3 sites open, goal 20 by year-end.
- Declared 15% stock dividend (0.15 shares/share) payable Aug 21, 2025 to holders of record Aug 7.
- Completed 15:1 reverse stock split effective July 25; Nasdaq listing extension granted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315225011597/0001493152-25-011597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315225011597/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-011597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer